BridgeMD
New treatment option for Chemotherapy-Induced Peripheral Neuropathy
Official title Extracellular Vesicles and Chemotherapy-Induced Peripheral Neuropathy
ClinicalTrials.gov ID: NCT07558447
What this study is testing
- What it's testing
- The goal of this clinical trial is to learn whether extracellular vesicles (EVs) in the blood can be used as biomarkers to predict chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer patients receiving chemotherapy with taxanes, platinum compounds, or antimitotic drugs. The main questions the study aims to answer are whether blood levels of EVs change in patients who develop CIPN during and after chemotherapy and whether specific features of EVs, including lipids and microRNAs, are associated with the development and severity of CIPN.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Has signed the informed consent form
- Is 18 years of age or older
- Is male or female
- Has breast cancer and is scheduled to receive paclitaxel, docetaxel, eribulin, capecitabine, or carboplatin as part of standard care
- Has gastrointestinal cancer and is scheduled to receive oxaliplatin or capecitabine as part of standard care
You likely can't join if
- Has already been diagnosed with CIPN
- Has a neurodegenerative disease
See the full eligibility criteria
- Has signed the informed consent form
- Is 18 years of age or older
- Is male or female
- Has breast cancer and is scheduled to receive paclitaxel, docetaxel, eribulin, capecitabine, or carboplatin as part of standard care
- Has gastrointestinal cancer and is scheduled to receive oxaliplatin or capecitabine as part of standard care
- Has lung cancer and is scheduled to receive cisplatin, carboplatin, or docetaxel as part of standard care
- Has urologic cancer and is scheduled to receive carboplatin, cisplatin, paclitaxel, docetaxel, or enfortumab vedotin as part of standard care
- Has head and neck cancer and is scheduled to receive carboplatin, paclitaxel, or cisplatin as part of standard care
- Has already been diagnosed with CIPN
- Has a neurodegenerative disease
The study team makes the final eligibility decision.
Where it's taking place
- Milan, Italy
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Milan, Italy. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.